More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$26263453
EPS
-2.11
P/E ratio
--
Price to sales
0.05
Dividend yield
--
Beta
4.347088
Previous close
$0.80
Today's open
$0.80
Day's range
$0.76 - $0.81
52 week range
$0.66 - $6.48
show more
CEO
Robert W. Leasure
Employees
2055
Headquarters
WEST LAFAYETTE, IN
Exchange
NASDAQ Capital Market
Shares outstanding
34367251
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Inotiv Partners with VUGENE to Advance AI-Driven Drug Discovery and Bioinformatics Capabilities
WEST LAFAYETTE, Ind., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading Contract Research Organization (CRO) specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, and VUGENE, a multi-omics data analysis company providing advanced artificial intelligence (AI) and machine learning (ML) solutions for biomedical research, today announced a strategic collaboration designed to accelerate AI-assisted drug discovery and enhance data-driven insights across the drug development continuum.
GlobeNewsWire • Dec 11, 2025

Inotiv, Inc. (NOTV) Q4 2025 Earnings Call Transcript
Inotiv, Inc. (NOTV) Q4 2025 Earnings Call Transcript
Seeking Alpha • Dec 4, 2025

Inotiv Reports Fourth Quarter and Full Year Financial Results for Fiscal 2025 and Provides Business Update
– Fourth quarter fiscal 2025 revenue up 5.9% to $138.1 million– Fiscal 2025 revenue increased 4.5% to $513.0 million– Fourth quarter fiscal 2025 operating loss decreased 48.5% to $6.8 million– Fiscal 2025 operating loss decreased 64.2% to $30.9 million– Conference call scheduled for today at 4:30 pm ET
GlobeNewsWire • Dec 3, 2025

Inotiv Ranked Number 182nd Fastest-Growing Company in North America on the 2025 Deloitte Technology Fast 500™
Building a Unified, Client-Focused, Early Stage CRO Through Strategic Expansion and Service Development Powers 448% Revenue Growth from Fiscal Year 2021 to Fiscal Year 2024 Building a Unified, Client-Focused, Early Stage CRO Through Strategic Expansion and Service Development Powers 448% Revenue Growth from Fiscal Year 2021 to Fiscal Year 2024
GlobeNewsWire • Nov 25, 2025

Inotiv, Inc. to Report Fiscal 2025 Fourth Quarter and Full Year Financial Results and Host Conference Call on Wednesday, December 3, 2025
WEST LAFAYETTE, Ind., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2025 fourth quarter and full year ended September 30, 2025, on Wednesday, December 3, 2025, after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results.
GlobeNewsWire • Nov 21, 2025

Top 3 Health Care Stocks Which Could Rescue Your Portfolio In November
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Benzinga • Nov 18, 2025

Inotiv, Inc. Announces Preliminary Fiscal 2025 Fourth Quarter and Full Year Results
Preliminary Expected Fourth Quarter 2025 Revenue of $137.5 to $138.5 Million Preliminary Expected Full Year 2025 Revenue of $512.5 to $513.5 Million
GlobeNewsWire • Nov 17, 2025

Halper Sadeh LLC Encourages Inotiv, Inc. Shareholders to Contact the Firm to Discuss Their Rights
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Inotiv, Inc. (NASDAQ: NOTV) breached their fiduciary duties to shareholders. If you currently own Inotiv stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about your legal righ.
Business Wire • Oct 24, 2025

Inotiv, Inc. to Participate in Three Investor Conferences in September 2025
WEST LAFAYETTE, Ind., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that Robert Leasure Jr., President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer, will participate in the upcoming H.C. Wainwright 27th Annual Global Investment Conference, the Baird Global Healthcare Conference and the Lake Street Capital Markets 9th Annual Best Ideas Growth Conference.
GlobeNewsWire • Aug 13, 2025

Inotiv, Inc. (NOTV) Q3 2025 Earnings Call Transcript
Inotiv, Inc. (NASDAQ:NOTV ) Q3 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Beth A. Taylor - Senior VP of Finance & CFO John E.
Seeking Alpha • Aug 7, 2025

¹ Disclosures

Open an M1 investment account to buy and sell Inotiv Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.